Amicus Therapeutics Stock Forecast, Price & News

-0.07 (-0.74 %)
(As of 08/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.51 million shs
Average Volume3.19 million shs
Market Capitalization$2.48 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive FOLD News and Ratings via Email

Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Amicus Therapeutics logo

About Amicus Therapeutics

Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Philadelphia, PA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.29 out of 5 stars

Medical Sector

254th out of 1,309 stocks

Pharmaceutical Preparations Industry

123rd out of 646 stocks

Analyst Opinion: 4.3Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Amicus Therapeutics (NASDAQ:FOLD) Frequently Asked Questions

Is Amicus Therapeutics a buy right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There are currently 7 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Amicus Therapeutics stock.
View analyst ratings for Amicus Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Amicus Therapeutics?

Wall Street analysts have given Amicus Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Amicus Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Amicus Therapeutics' next earnings date?

Amicus Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Amicus Therapeutics

How can I listen to Amicus Therapeutics' earnings call?

Amicus Therapeutics will be holding an earnings conference call on Thursday, August 5th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 404-537-3406 with passcode "7374935".

How were Amicus Therapeutics' earnings last quarter?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) posted its quarterly earnings results on Sunday, May, 9th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.24) by $0.01. The biopharmaceutical company had revenue of $66.40 million for the quarter, compared to the consensus estimate of $71.76 million. Amicus Therapeutics had a negative net margin of 95.05% and a negative trailing twelve-month return on equity of 80.85%.
View Amicus Therapeutics' earnings history

How has Amicus Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Amicus Therapeutics' stock was trading at $8.05 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, FOLD stock has increased by 15.9% and is now trading at $9.33.
View which stocks have been most impacted by COVID-19

What guidance has Amicus Therapeutics issued on next quarter's earnings?

Amicus Therapeutics issued an update on its FY 2021 earnings guidance on Tuesday, June, 8th. The company provided earnings per share (EPS) guidance of $- for the period. The company issued revenue guidance of $300 million-315 million, compared to the consensus revenue estimate of $312.64 million.

What price target have analysts set for FOLD?

14 brokers have issued 12 month target prices for Amicus Therapeutics' stock. Their forecasts range from $13.00 to $31.00. On average, they anticipate Amicus Therapeutics' stock price to reach $18.83 in the next year. This suggests a possible upside of 101.9% from the stock's current price.
View analysts' price targets for Amicus Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Amicus Therapeutics' key executives?

Amicus Therapeutics' management team includes the following people:
  • John Francis Crowley, Chairman & Chief Executive Officer
  • Bradley Lewis Campbell, President, Chief Operating Officer & Director
  • Daphne E. Quimi, Chief Financial Officer
  • Hung Do, Chief Science Officer
  • Patrik S. Florencio, Senior VP, Global Chief Compliance & Risk Officer

What is John F. Crowley's approval rating as Amicus Therapeutics' CEO?

21 employees have rated Amicus Therapeutics CEO John F. Crowley on John F. Crowley has an approval rating of 48% among Amicus Therapeutics' employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Amicus Therapeutics' key competitors?

What other stocks do shareholders of Amicus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

What is Amicus Therapeutics' stock symbol?

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

Who are Amicus Therapeutics' major shareholders?

Amicus Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include New York State Common Retirement Fund (0.36%), Peregrine Capital Management LLC (0.27%), Rice Hall James & Associates LLC (0.24%), Alliancebernstein L.P. (0.14%), Asymmetry Capital Management L.P. (0.11%) and Brinker Capital Investments LLC (0.04%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Bradley L Campbell, Burke W Whitman, Daphne Quimi, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, Lynn Dorsey Bleil, Margaret G Mcglynn, Michael Raab and Samantha Prout.
View institutional ownership trends for Amicus Therapeutics

Which major investors are selling Amicus Therapeutics stock?

FOLD stock was sold by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, Arizona State Retirement System, New York State Common Retirement Fund, Zurcher Kantonalbank Zurich Cantonalbank , Alliancebernstein L.P., and Advisor Group Holdings Inc.. Company insiders that have sold Amicus Therapeutics company stock in the last year include Bradley L Campbell, Daphne Quimi, Hung Do, Jay Barth, John F Crowley, Margaret G Mcglynn, and Samantha Prout.
View insider buying and selling activity for Amicus Therapeutics
or view top insider-selling stocks.

Which major investors are buying Amicus Therapeutics stock?

FOLD stock was purchased by a variety of institutional investors in the last quarter, including Asymmetry Capital Management L.P., Peregrine Capital Management LLC, Brinker Capital Investments LLC, and Advisors Asset Management Inc.. Company insiders that have bought Amicus Therapeutics stock in the last two years include Burke W Whitman, and Lynn Dorsey Bleil.
View insider buying and selling activity for Amicus Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Amicus Therapeutics?

Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amicus Therapeutics' stock price today?

One share of FOLD stock can currently be purchased for approximately $9.33.

How much money does Amicus Therapeutics make?

Amicus Therapeutics has a market capitalization of $2.48 billion and generates $260.89 million in revenue each year. The biopharmaceutical company earns $-276,850,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis.

How many employees does Amicus Therapeutics have?

Amicus Therapeutics employs 483 workers across the globe.

What is Amicus Therapeutics' official website?

The official website for Amicus Therapeutics is

Where are Amicus Therapeutics' headquarters?

Amicus Therapeutics is headquartered at 1 Cedar Brook Drive, Cranbury NJ, 08512.

How can I contact Amicus Therapeutics?

Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company can be reached via phone at (215) 921-7600 or via email at [email protected]

This page was last updated on 8/4/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.